Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Ashkenazi will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee through July 2024
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Bebtelovimab neutralizes Omicron as demonstrated by pseudo virus and authentic virus data
Expanded EUA includes both treatment of patients with Covid-19 and post-exposure prophylaxis (PEP) in high-risk pediatric and infant patients
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
